Progress in Parkinson's disease-where do we stand?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Progress in neurobiology

• Publication date

  2008-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.pneurobio.2008.05.003PMID 18582530
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Humic substances in the environment with an emphasis on freshwater systems

  2008cited by this paper
• Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease

  2007cited by this paper
• Repeated intracerebroventricular infusion of nicotine prevents kainate-induced neurotoxicity by activating the alpha7 nicotinic acetylcholine receptor.

  2007cited by this paper
• Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs.

  2007cited by this paper
• Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

  2007cited by this paper
• Derivation of Functional Dopamine Neurons from Embryonic Stem Cells

  2007cited by this paper
• ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease

  2007cited by this paper
• ERK 1/2 signaling pathway is involved in nicotine‐mediated neuroprotection in spinal cord neurons

  2007cited by this paper
• Treatment options in the modern management of Parkinson disease.

  2007cited by this paper
• Advances in the treatment of Parkinson's disease.

  2007cited by this paper
• Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

  2007cited by this paper
• Nicotine partially protects against paraquat‐induced nigrostriatal damage in mice; link to α6β2* nAChRs

  2007cited by this paper
• AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.

  2007cited by this paper
• Temporal relationship between cigarette smoking and risk of Parkinson disease

  2007cited by this paper
• Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.

  2007cited by this paper
• Coenzyme Q10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons

  2007cited by this paper
• The engrailed transcription factors and the mesencephalic dopaminergic neurons.

  2006cited by this paper
• Genetics of Parkinson disease: paradigm shifts and future prospects

  2006cited by this paper
• Epidemiology of Parkinson's disease.

  2006cited by this paper
• Developmental origin and fate of meso-diencephalic dopamine neurons.

  2006cited by this paper
• Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

  2006cited by this paper
• Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries

  2006cited by this paper
• Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys

  2006cited by this paper
• Crossroads in GDNF therapy for Parkinson's disease

  2006cited by this paper
• Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

  2006cited by this paper
• Neurobiology of Exercise

  2006cited by this paper
• Neurobiology of exercise

  2006cited by this paper
• Concise Review: Recent Advances on the Significance of Stem Cells in Tissue Regeneration and Cancer Therapies

  2006cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• Genetic causes of Parkinson's disease: extending the pathway.

  2006cited by this paper
• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

  2006cited by this paper
• The therapeutic potential of monoamine oxidase inhibitors

  2006cited by this paper
• Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study

  2005cited by this paper
• Cost of disorders of the brain in Europe

  2005cited by this paper
• Stimulation of nicotinic acetylcholine receptors protects motor neurons.

  2005cited by this paper
• Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis.

  2005cited by this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cited by this paper
• Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease.

  2005cited by this paper
• Current Neurosurgical Treatments for Parkinson's Disease. Where Did They Come From?

  2005cited by this paper
• Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.

  2005cited by this paper
• Risk and protective factors for Parkinson's disease: A study in Swedish twins

  2005cited by this paper
• Stem cells may reshape the prospect of Parkinson's disease therapy.

  2005cited by this paper
• Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10.

  2005cited by this paper
• Molecular pathophysiology of Parkinson's disease.

  2005cited by this paper
• Exercise Enhances Learning and Hippocampal Neurogenesis in Aged Mice

  2005cited by this paper
• The floor plate: multiple cells, multiple signals

  2005cited by this paper
• Burden of illness in Parkinson's disease

  2005cited by this paper
• Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

  2005cited by this paper
• Cost of Parkinson's disease in Europe

  2005cited by this paper
• Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain

  2005cited by this paper
• Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

  2005cited by this paper
• The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

  2005cited by this paper
• Early Environmental Origins of Neurodegenerative Disease in Later Life

  2005cited by this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cited by this paper
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

  2004cited by this paper
• Stem cell therapy for human neurodegenerative disorders–how to make it work

  2004cited by this paper
• Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10.

  2004cited by this paper
• Smoking and Parkinson's disease: Systematic review of prospective studies

  2004cited by this paper
• Genetic clues to the pathogenesis of Parkinson's disease

  2004cited by this paper
• Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease.

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor

  2004cited by this paper
• Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

  2004cited by this paper
• Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

  2004cited by this paper
• Parkinson's disease

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.

  2004cited by this paper
• Frequency-dependent modulation of dopamine release by nicotine

  2004cited by this paper
• Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra

  2004cited by this paper
• Mutant genes responsible for Parkinson's disease.

  2004cited by this paper
• Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members

  2004cited by this paper
• Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3

  2004cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1

  2004cited by this paper
• Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.

  2004cited by this paper
• Changing patterns of adult (45-74 years) neurological deaths in the major Western world countries 1979-1997.

  2004cited by this paper
• Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease

  2004cited by this paper
• Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients.

  2003cited by this paper
• Differential Desensitization and Distribution of Nicotinic Acetylcholine Receptor Subtypes in Midbrain Dopamine Areas

  2003cited by this paper
• Significant linkage of Parkinson disease to chromosome 2q36-37.

  2003cited by this paper
• Randomized trial of pallidotomy versus medical therapy for Parkinson's disease

  2003cited by this paper
• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

  2003cited by this paper
• Transcriptional Control of Dopamine Neuron Development

  2003cited by this paper
• Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

  2003cited by this paper
• Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a

  2003cited by this paper
• Pitx3 is required for development of substantia nigra dopaminergic neurons

  2003cited by this paper
• Economic burden and quality of life impairment increase with severity of PD.

  2003cited by this paper
• Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells

  2003cited by this paper
• A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

  2003cited by this paper
• Selenium and selenoproteins in the brain and brain diseases

  2003cited by this paper
• Dose‐dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences

  2003cited by this paper
• Poor Tolerability of a Transdermal Nicotine Treatment in Parkinson's Disease

  2003cited by this paper
• Neuronal generation from somatic stem cells: current knowledge and perspectives on the treatment of acquired and degenerative central nervous system disorders.

  2003cited by this paper
• Physiology and Pathophysiology of Parkinson's Disease

  2003cited by this paper
• Multidisciplinary rehabilitation for people with Parkinson’s disease: a randomised controlled study

  2003cited by this paper
• The burden of brain diseases in Europe

  2003cited by this paper
• Description of Parkinson's Disease as a Clinical Syndrome

  2003cited by this paper
• Mutations in NR4A2 associated with familial Parkinson disease

  2003cited by this paper
• Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons

  2003cited by this paper
• Direct economic impact of Parkinson's disease: A research survey in the United Kingdom

  2003cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper

• Bioelectronics hydrogels for implantable cardiac and brain disease medical treatment application.

  2025cites this paper
• Activating Wnt1/β-Catenin signaling pathway to restore Otx2 expression in the dopaminergic neurons of ventral midbrain.

  2025cites this paper
• Application of injectable hydrogels in the central and peripheral nervous system as a unique and flexible platform for neural tissue repair

  2025cites this paper
• Novel Insights Into the Causal Effects and Shared Genetics Between Body Fat and Parkinson Disease

  2024cites this paper
• Injectable Hierarchical Bioactive Hydrogels with Fibroblast Growth Factor 21/Edaravone/Caffeic Acid Asynchronous Delivery for Treating Parkinson's Disease

  2024cites this paper
• Detection of the source of Parkinson treatment inefficiency using machine learning based on tremor signals

  2024cites this paper
• Single and Multi-modal Analysis for Parkinson’s Disease to Detect Its Underlying Factors

  2024cites this paper
• Phytomedicine Nanoformulations for Parkinson's disease

  2024cites this paper
• Targeting Microglia in Neuroinflammation: H3 Receptor Antagonists as a Novel Therapeutic Approach for Alzheimer’s Disease, Parkinson’s Disease, and Autism Spectrum Disorder

  2024cites this paper
• A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A

  2023cites this paper
• Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases

  2023cites this paper
• Neuroprotective Effects of Licochalcone D in Oxidative-Stress-Induced Primitive Neural Stem Cells from Parkinson’s Disease Patient-Derived iPSCs

  2023cites this paper
• Self-healing hydrogel as an injectable implant: translation in brain diseases

  2023cites this paper
• THE POTENT AND SELECTIVE HISTAMINE H3 RECEPTOR ANTAGONIST E169 ALLEVIATES COGNITIVE DEFICITS AND MITIGATES DISTURBED PI3K/AKT/GSK-3Β SIGNALING PATHWAY IN MK801 -INDUCED AMNESIA IN MICE

  2023cites this paper
• Nardostachys jatamansi and levodopa combination alleviates Parkinson’s disease symptoms in rats through activation of Nrf2 and inhibition of NLRP3 signaling pathways

  2023cites this paper
• Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With Parkinson Disease—A Pilot Study

  2023cites this paper
• Bioactive self-healing hydrogel based on tannic acid modified gold nano-crosslinker as an injectable brain implant for treating Parkinson’s disease

  2023cites this paper
• The effects of physiotherapy treatments on dysphagia in Parkinson's disease: a systematic review of randomized controlled trials.

  2022cites this paper
• 6-Hydroxydopamine Induces Abnormal Iron Sequestration in BV2 Microglia by Activating Iron Regulatory Protein 1 and Inhibiting Hepcidin Release

  2022cites this paper
• Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease

  2022cites this paper
• Single-cell transcriptomics reveals the cell fate transitions of human dopaminergic progenitors derived from hESCs

  2022cites this paper
• Induced neural stem cells from Macaca fascicularis show potential of dopaminergic neuron specification and efficacy in a mouse Parkinson's disease model.

  2022cites this paper
• Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

  2021cites this paper
• The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease

  2021cites this paper
• Dual-task intervention based on trail making test: Effects on Parkinson's disease.

  2021cites this paper
• Recuperative effect of estrogen on rotenone-induced experimental model of Parkinson’s disease in rats

  2021cites this paper
• Potential protective role of astrocytes in the pathogenesis of astrocyte-mediated synaptic plasticity of Parkinson's disease.

  2021cites this paper
• Effect of ginsenoside-Rg1 on experimental Parkinson's disease: A systematic review and meta-analysis of animal studies

  2021cites this paper
• T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson’s disease

  2020cites this paper
• Co-administration of TiO2-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury.

  2020cites this paper
• Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside

  2020cites this paper
• The class II histone deacetylases as therapeutic targets for Parkinson’s disease

  2020cites this paper
• Redox toxicology of environmental chemicals causing oxidative stress

  2020cites this paper
• Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

  2019cites this paper
• A nutritional approach to microbiota in Parkinson’s disease

  2019cites this paper
• 9 Simulating Idiopathic Parkinson ’ s Disease by In Vitro and Computational Models

  2019cites this paper
• PPARß/&dgr; agonist alleviates NLRP3 inflammasome‐mediated neuroinflammation in the MPTP mouse model of Parkinson's disease

  2019cites this paper
• Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats

  2019cites this paper
• Long-term Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease.

  2018cites this paper
• A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced Excitotoxicity

  2018cites this paper
• Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease

  2018cites this paper
• Title The potential of neurotrophic factors for the treatment of Parkinson ' s disease

  2018influential citation
• Ceruloplasmin in Parkinson's disease and the nonmotor symptoms

  2018cites this paper
• Potential Effects of Pomegranate Juice in Attenuating LID in Mice Model of Parkinson Disease

  2018cites this paper
• Gut and Parkinson’s disease

  2018cites this paper
• 9 Simulating Idiopathic Parkinson ’ s Disease by In Vitro and Computational Models

  2017cites this paper
• Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis.

  2017cites this paper
• Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration

  2017cites this paper
• Manganese chloride induces histone acetylation changes in neuronal cells: Its role in manganese‐induced damage

  2017cites this paper
• Pentazocine Protects SN4741 Cells Against MPP+-Induced Cell Damage via Up-Regulation of the Canonical Wnt/β-Catenin Signaling Pathway

  2017cites this paper
• Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

  2017cites this paper
• Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease.

  2017cites this paper
• Stereological Analysis of the Brain in Methamphetamine Abusers Compared to the Controls

  2017cites this paper
• Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.

  2017cites this paper
• Supplementation with Herbal Extracts to Promote Behavioral and Neuroprotective Effects in Experimental Models of Parkinson's Disease: A Systematic Review

  2017influential citation
• Interaction between diet composition and gut microbiota and its impact on gastrointestinal tract health

  2017cites this paper
• Stereological Evaluation of the Brains in Patients with Parkinson’s disease Compared to Controls

  2017cites this paper
• Potential molecular mechanisms mediating the protective effects of tetrahydroxystilbene glucoside on MPP+-induced PC12 cell apoptosis

  2017cites this paper
• Embryonic development of selectively vulnerable neurons in Parkinson’s disease

  2017cites this paper
• mGlu5 Receptors in Parkinson’s Disease and MPTP-Lesioned Monkeys: Behavior and Brain Molecular Correlates

  2017cites this paper
• Distinct alterations in motor & reward seeking behavior are dependent on the gestational age of exposure to LPS-induced maternal immune activation.

  2017cites this paper
• Protocol for evaluation of neurotrophic strategies in Parkinson’s disease-related dopaminergic and sympathetic neurons in vitro

  2016cites this paper
• The rise and fall of mesodiencephalic dopaminergic neurons Molecular programming by transcription factors Engrailed 1, Pitx3, and Nkx2.9 during the development of mesodiencephalic neurons

  2016cites this paper
• The rise and fall of mesodiencephalic dopaminergic neurons Molecular programming by transcription factors Engrailed 1, Pitx3, and Nkx2.9 during the development of mesodiencephalic neurons

  2016cites this paper
• Development of a Prolonged-Release Pramipexole Transdermal Patch: In Vitro and In Vivo Evaluation

  2016cites this paper
• Parkinson's disease and periodontitis - the missing link? A review.

  2016cites this paper
• Plant-Derived Natural Products for Parkinson's Disease Therapy.

  2016cites this paper
• The rise and fall of mesodiencephalic dopaminergic neurons Molecular programming by transcription factors Engrailed 1, Pitx3, and Nkx2.9 during the development of mesodiencephalic neurons

  2016cites this paper
• The rise and fall of mesodiencephalic dopaminergic neurons Molecular programming by transcription factors Engrailed 1, Pitx3, and Nkx2.9 during the development of mesodiencephalic neurons

  2016cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper
• Development of stem cell-based therapies for Parkinson's disease

  2016cites this paper
• L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.

  2016cites this paper
• Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism

  2016cites this paper
• Conformational, Optoelectronic and Vibrational Properties of the Entacapone Molecule: A Quantum Chemistry Study.

  2016cites this paper
• Contributions of central and systemic inflammation to the pathophysiology of Parkinson ’ s disease

  2016influential citation
• Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects

  2016cites this paper
• mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias

  2016cites this paper
• The Benefits of Natural Products for Neurodegenerative Diseases

  2016cites this paper
• Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms.

  2016cites this paper
• Salidroside Protects Against 6-Hydroxydopamine-Induced Cytotoxicity by Attenuating ER Stress

  2016cites this paper
• Evaluation of helper-dependent canine adenovirus vectors in a 3D human CNS model

  2015cites this paper
• Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs

  2015cites this paper
• Brain region-specific microglial phenotypes and responses in Parkinson’s disease

  2015cites this paper
• Myricitrin alleviates MPP⁺-induced mitochondrial dysfunction in a DJ-1-dependent manner in SN4741 cells.

  2015cites this paper
• Epicatechin Reduces Striatal MPP+-Induced Damage in Rats through Slight Increases in SOD-Cu,Zn Activity

  2015cites this paper
• In Vivo Neuroprotective Effects of Cinnamon Bioactive Compounds in C. elegans and D. melanogaster

  2015influential citation
• NALP3 inflammasome activation in protein misfolding diseases.

  2015cites this paper
• Viral vector delivery of neurotrophic factors for Parkinson's disease therapy

  2015cites this paper
• Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease

  2015cites this paper
• Evaluation of helper-dependent canine adenovirus 1 vectors in a 3 D human CNS model 2 3

  2015cites this paper
• Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson’s Disease-Related LRRK2 G2019S Mutation

  2015cites this paper
• Evaluation of the Development of R&D into Parkinson's Disease through Technology Monitoring Using Patent Documents and Scientific Articles

  2015cites this paper
• Neuroprotection in a rotenone model of Parkinson's disease

  2015influential citation
• Protective effects of apigenin against 1-methyl-4-phenylpyridinium ion‑induced neurotoxicity in PC12 cells.

  2015cites this paper
• Modulation of Microglial Activity by GDNF

  2015cites this paper
• The neuroprotective effect of lovastatin on MPP(+)-induced neurotoxicity is not mediated by PON2.

  2015cites this paper
• Inflammatory and cell death pathways in brain and peripheral blood in Parkinson's disease.

  2015cites this paper
• Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT

  2015cites this paper
• Estela Protein intake and the use of levodopa in patients with Parkinson ’ s disease

  2015influential citation
• Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease

  2015cites this paper